Back to Journals
Drug Design, Development and Therapy
Prof. Dr. Boeckler
1Laboratory for Molecular Design and Pharmaceutical Biophysics, Department of Pharmaceutical and Med, Eberhard-Karls University Tuebingen, Germany
Editor-in-Chief: Prof. Dr. Frank Boeckler
Dr. Boeckler is a W3 Professor of Medicinal Chemistry and Drug Design at the Department of Pharmacy and Biochemistry at Eberhard Karls University in Tuebingen. Since 2014, he is also member of the Center of Bioinformatics (ZBIT) of the University of Tuebingen. At the Institute of Pharmaceutical Sciences, he is head of the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry and Molecular Design. His work is dedicated to understanding molecular interactions as the foundation for chemical biology and drug discovery, to apply theoretical and biophysical methods to cancer research, and to develop novel peptide-based toolkits.
Studying receptor-ligand interactions in GPCR drug discovery from computational models to pharmacological consequences, Dr. Boeckler received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). He specialized in computational chemistry and drug design, ranging from QM methods to in silico screening. As a visiting scientist, he did research projects at the ETH Zurich (Behavioral Neurobiology) and at the Philipps University Marburg (Drug Design). In 2006, he joined Prof. Sir Alan R. Fersht at the MRC Center for Protein Engineering in Cambridge/UK as DFG and later Marie Curie fellow and discovered there p53 mutant stabilizers as potential new cancer therapeutics (PNAS 2008, 105, 10360). While working in Cambridge at the interface of experiment and theory, he focused on molecular biology and biophysics. In 2008, he was appointed as Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich. In 2010, he moved to Eberhard Karls University Tuebingen as Professor for Medicinal Chemistry/Drug Design, where he now heads the Laboratory for Molecular Design & Pharmaceutical Biophysics. Since 2008, his lab has been developing methods and tools for improving the understanding and applicability of molecular interactions, particularly halogen bonding (XB). As innovative interactions, based on electron anisotropy and the formation of the σ-hole, halogen bonds bear the potential to extent the chemical space of pharmacophores in ligands targeting certain areas of the biological space (J. Med. Chem. 2013, 56, 1363). Tools and methods developed in the Boeckler lab range from XB scoring functions (J. Chem. Inf. Model. 2015, 55, 687) to halogen-enriched fragment libraries (JACS 2012, 134, 6810).
乐动体育西班牙人Dr. Boeckler serves as member of different Scientific and Editorial Advisory Boards. In 2015 he has joined the team of editors of the RÖMPP Encyclopedia covering the area of Pharmacy and Medicine. He has received multiple awards, including the Klaus-Grohe prize in Medicinal Chemistry, as well as the European Federation of Medicinal Chemistry (EFMC) Young Medicinal Chemist in Academia Prize (2016).
乐动体育西班牙人Professor of Medicine at Houston Methodist Research Institute, Faculty Member of the Department of Medicine at Weill Cornell Medical College, United States
Associate Editor: Dr Tuo Deng
Dr. Deng earned a Bachelor Degree with honor from Peking University and obtained a Ph. D. in Biology from Tsinghua University in 2006. He is currently an Assistant Professor of Medicine at Houston Methodist Research Institute and a faculty member of the Department of Medicine at Weill Cornell Medical College.
Dr. Deng began the study on metabolic diseases in 2001, and continued his research in the field of obesity and diabetes. In his Ph.D. study, Dr. Deng has conducted vital studies elucidating the target genes of PPARgamma, as well as discovering and developing novel PPAR ligands for the treatment of type 2 diabetes and other metabolic diseases. During his study in Chipscreen Biosciences, Dr. Deng made significant contributions to discover a serious of PPAR agonists and HDAC inhibitors for the treatment of diabetes and cancer. He is the co-inventor of a number of granted patents.
During his postdoctoral training, Dr. Deng was focused on the identification of the trigger signal of obesity-induced adipose inflammation, which is the major contributor of most obesity related diseases. He made the paradigm shattering discovery that adipocyte MHCII (class II major histocompatibility complex) triggers obesity-induced adipose inflammation by initiating adipose resident T cell activation, suggesting that the adipocytes act as antigen presenting cells to initiate obesity-induced adipose inflammation and systemic complications. This study was published in Cell Metabolism as a cover story and, in turn, attracted attention with editorials in many of the leading scientific journals and in the local and national press and formed the basis of his successful AHA young scientist award. At this stage of his career, Dr. Deng has continued to investigate adipose inflammation and obesity-related diseases.
Assistant Professor, Biomedical Engineering Department, Southern University of Science and Technology, China (PRC)
Associate Editor: Dr Qiongyu Guo
乐动体育西班牙人Dr. Guo is an assistant professor at the Southern University of Science and Technology, Shenzhen, China. She earned her BS degree in Polymer Science and Engineering from the University of Science and Technology of China in 2004. She obtained her PhD in Macromolecular Science and Engineering at the Case Western Reserve University in 2010. She received her postdoctoral training in Biomedical Engineering at the Johns Hopkins University. She has authored 20 peer-reviewed research publications and review articles. Her research focuses on engineering biomaterials through translational approaches so that the clinical use may be realized to enhance human health and well-being. She specialized in developing drug delivery systems and functional biomaterials for tissue engineering and cancer treatments. She has extensive experience on biodegradable drug-eluting stent, shape memory nanosystem, light activated cell migration, biomimetic artificial cornea and musculoskeletal regeneration.
乐动体育西班牙人Department of Pharmaceutical Sciences, Nova Southeastern University, United States
Associate Editor: Dr Anastasios Lymperopoulos (PhD, FAHA, FESC)
My career started by earning M.Sc. in Medicinal Chemistry followed by Ph.D. in Pharmacology, after graduating from the School of Pharmacy of the University of Patras, Greece. Its major turning point was in 2004, when I joined the lab of Dr. Walter Koch, a former postdoctoral fellow of Nobel laureate Professor Robert Lefkowitz`s lab at Duke University. During my 5-year postdoctoral tenure there, I had several successes, awards and honors, most prominent among which my elections as Fellow of the American Heart Association (FAHA) with its Council on Basic Cardiovascular Sciences (BCVS) and as Fellow of the European Society of Cardiology (FESC), as well as a 5-year Scientist Development Grant award from the American Heart Association (AHA). In addition, I have been an AHA post-doctoral research fellow for a total of three years in the past, and, in fact, my postdoctoral fellowship application with AHA in 2007 got an unusual 1-year extension based on its exceptionally high score. I have also been a finalist for the AHA-sponsored Melvin L. Marcus Young Investigator Award in Basic Cardiovascular Sciences, and for the Cardiovascular Research Award of the Council on Basic Cardiovascular Sciences of the European Society of Cardiology (ESC), I hold three (provisional) research patents, and I currently serve as associate editor of four peer-reviewed journals, published by esteemed publishers (British Pharmacological Society, Wolters Kluwer Health, Dove Medical Press). I have edited one textbook published by Springer and authored several book chapters. I also serve as a regular peer-reviewer for several prestigious journals, including “British Journal of Pharmacology”, "Circulation Research", and “American Journal of Cardiology”. Finally, I have published in various prestigious scientific journals: Nature Medicine; Circulation; JACC; PNAS; JBC, Circ. Res., to name a few (for an extensive list of my >50 peer-reviewed publications see MEDLINE) and my h-index is 13 (>1000 total citations, as of January 2016). I currently serve as NSU College of Pharmacy faculty at the Associate Professor level and mentor several PhD and PharmD students in cardiovascular research in my lab.
Pharmaceutical Chemistry, University of Vienna, Austria
Associate Editor: Professor Manfred Ogris
乐动体育西班牙人Dr Ogris is Professor for Pharmaceutical Sciences at the University of Vienna and Head of the Laboratory for Macromolecular Cancer Therapeutics (MMCT). After studying biotechnology at the University of Natural Resources and Life Sciences in Vienna, he carried out his PhD at the Vienna Biocenter on the development and in vivo application of tumor targeted, polycation based gene delivery systems. During his postdoctoral stay at the CRC Institute of Cancer Research, University of Birmingham/UK, he worked on peptide based endosomal escape mechanisms to improve synthetic gene delivery systems. In 2001, Dr Ogris joined the Faculty of Pharmacy and Chemistry at the Ludwig-Maximilians-University Munich as a work group leader at the Chair of Pharmaceutical Biology and Pharmaceutical Biotechnology. The focus of his ‘Vectorology’ research group was to develop specific and efficient plasmid and siRNA based nucleic acid vectors for treatment of metastatic cancers in combination with chemo- and radiation therapy. In 2009, Dr Ogris obtained his venia docendi (habilitation) for Pharmaceutical Biology and Pharmaceutical Biotechnology. In 2013, he was appointed as a full professor for Pharmaceutical Biotechnology at the Department for Pharmaceutical Chemistry, Faculty of Life Sciences of the University Vienna, where he founded and heads the MMCT lab. The lab has a strong focus on the development of macromolecular formulations for targeted drug delivery and the development of nucleic acid based therapies.
乐动体育西班牙人Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, United Kingdom
Associate Editor: Dr Georgios D. Panos
Dr Georgios D. Panos received his medical degree from the Aristotle University of Thessaloniki, Greece in 2007. Following his graduation, he attended a Cataract & Anterior Segment research fellowship in Ophthalmology at Papageorgiou Hospital, Aristotle University of Thessaloniki, Greece (2007-2009). He completed his residency training in Ophthalmology at the Cantonal Hospital of Fribourg, Switzerland, at the University General Hospital of Alexandroupolis, Greece and at the Geneva University Hospitals, Switzerland and received his Certificate of Completion of Training in 2013. From October 2012 to December 2014 he was "Chef de Clinique" (Chief Resident – Junior Faculty Staff Member) in Neuro-ophthalmology & Paediatric Ophthalmology at the Geneva University Hospitals and Tutor of Ophthalmology at the Faculty of Medicine, University of Geneva, Switzerland. In 2013 he obtained his Doctorate Degree in Medicine (research MD, Clinical Research in Medical Retina, Ophthalmology) from the University of Geneva, Switzerland. He completed his first Medical Retina & Cataract Surgery fellowship at the Ipswich Hospital NHS Trust, University of Cambridge, UK in 2017. Since September 2017, he has been Senior Medical Retina & Cataract Fellow at Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. Since September 2015, he has been Invited Faculty Staff Member in the context of the postgraduate Master Degree program “Imaging in Ophthalmology” at the Democritus University of Thrace, Greece.
乐动体育西班牙人His main areas of research interest are ocular pharmacology, medical retina, uveitis, glaucoma, cataract and vitreoretinal surgery.
Microbiology and Immunology, Guanghua School of Stomatology at Sun Yat-Sen University, China (PRC)
Associate Editor: Professor Jianbo Sun
Dr. Sun is a Professor of Microbiology and Immunology at Guanghua School of Stomatology at Sun Yat-Sen University in Guangzhou. The two main interests of Dr. Sun's lab are molecular mechanism of promoting and suppressing immune response by B cells, and the application of immunotherapy drugs immobilized by magnetic nanoparticles in cancer prevention and precision treatment.
Dr. Sun received his Ph.D in Microbiology and Nanomedicine in 2007 in China Agricultural University after studing the high yield technology, biocompatibility and application of magnetosomes as nano drug carriers in tumor therapy. He obtained his first postdoctoral training in Icahn School of Medicine at Mount Sinai from 2008 to 2011. He studied there the mechanistic characterizations and functions of transcriptional factor and phosphatase Eya1 and its cofactors Six1, Sox2 and AthoI during the development and growth of vertebrate inner ear and kidney as well as in sensory neurogenesis. Then he moved to the Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University. There, he served as Postdoctoral Research Scientist and then Associate Research Scientist. He studied molecular mechanism of regulatory B cell biogenesis and function, and the mechanism of antibody diversification, genomic instability and oncogenesis resulted from AID and its cofactors such as RNA Exosome, RNA polymerase II and others.
Dr. Sun has 3 authorized patents, 2 book chapters, and 17 papers published in prestigious journals. And his publications are cited more than 450. Dr. Sun also serves as editor for The Internet Journal of Medical Informatics, guest editor for Bio-Medical Materials and Engineering, Technology Program Chair of The 3rd and 4th International Conference on Biomedical Engineering and Biotechnology (iCBEB 2014 and 2015), and Reviewer for 8 reputable journals.
Prof. Dr. Tanase
乐动体育西班牙人Department of Biochemistry/Proteomics, Victor Babes National Institute of Pathology, Romania
Associate Editor: Cristiana Tanase
乐动体育西班牙人Cristiana Tanase is an MD, PhD, Prof. Habil, Senior Researcher, and the Head of Biochemistry-Proteomics Department, “Victor Babes” National Institute of Pathology. She is a Habilitated Professor of Molecular Biology, Clinical Biochemistry, Research Management “Titu Maiorescu” University, Faculty of Medicine. Her research areas include proteomics, biomarkers, stem cells, pathology, tumor pathology, immunology, genetics, nanomedicine, and alternative therapies. She has completed over 60 national and international projects, leading 25; 8 internationally financially supported; FP7/Horizon 2020 and EuroNanoMed Expert Evaluator. She is a reviewer of 40 international journals, board member of 3 journals and Editor-in-Chief of Journal of Immunoassay & Immunochemistry, Inventor of 7 patents. She has published more than 100 papers/books. Her Hirsch index is 14 (Thomson Reuters), 18 (Google Scholar).
乐动体育西班牙人Biochemistry, UT Southwestern Medical Center, United States
Associate Editor: Dr Sukesh Voruganti
乐动体育西班牙人Dr. Voruganti is a Research Scientist at UT Southwestern Medical Center in Dallas, Texas. He obtained his PhD in Pharmaceutical Sciences from Texas Tech University Health Sciences Center after earning Bachelors of Pharmacy from Jawaharlal Nehru Technological University, India. He currently serves on editorial boards of four peer-reviewed international journals, as a regular peer-reviewer for several prestigious journals. Dr. Voruganti is an expert research scientist with a rare combination of molecular biology, pharmacology, and drug delivery. His research interests have been focussed on cancer drug discovery and development, drug metabolism and pharmacokinetics, pharmacokinetics/pharmacodynamic evaluations, gene and drug delivery with focus on developing formulations for improved bioavailability, safety and targeting.
Associate Editor: Professor Dr Wong Tin Wui
Professor Dr Wong Tin Wui obtained his PhD degree from National University of Singapore in 1999. He is presently the lecturer and research fellow at Universiti Teknologi MARA, Malaysia. His research areas are primarily focused on particle/scaffold design for targeted oral, transdermal and pulmonary drug delivery. His current research interests are innovative use of microwave as skin penetration enhancer for transdermal/topical drug delivery, development of nanoparticle formation processes and design of nanoparticles for diabetes as well as lung, skin and colorectal cancer treatment/prevention. He has authored more than 110 journal and 20 chapter publications in the field of drug delivery. He is the founder of Non-Destructive Biomedical and Pharmaceutical Research Centre in Malaysia and PharmaTech/PharmaSci - International Conference and Exhibition on Pharmaceutical, Nutraceutical and Cosmeceutical Sciences and Technology.
Tianjin Key Lab of modern Chinese medicine, Tianjin Univ. of TCM, China (PRC)
Country Editor (PR China): Professor Yan Zhu
Professor Yan Zhu obtained his PhD from Harvard University and completed postdoctoral trainings at Harvard Medical School and Brigham and Women's Hospital in Boston. He started his research career as assistant professor at Tufts University School of Medicine, as one of the founding members and an investigator of the Molecular Cardiology Research Center. He also served as director of Laboratory of Molecular Physiology at St. Elizabeth Medical Center, and director of research operation in Molecular Cardiology Research Institute at Tufts Medical Center. He held several adjunct lecture professorships in China, including Chinese Academy of Medical Sciences and Nankai University. In 2011, he returned to China as a recruit of the Tianjin “Qian-Ren Ji-Hua” talent program and now works full-time as a professor of Tianjin University of Traditional Chinese Medicine. He currently serves as the executive associate director of the Tianjin State Key Laboratory of Modern Chinese Medicine and director of R & D Center of Chinese Medicine at Tianjin International Joint Academy of Biomedicine.
Professor Zhu has been engaged in cardiovascular studies by combining molecular biology, physiology and pharmacology. His research has been supported by grants from NIH RO1 in USA and MOST 973 project in China. He has published more than 70 research articles in peer-reviewed international journals such as Science, Nature Medicine, and PNAS. His current research focuses on phenotype-based drug screen and discovery from herbal and other natural resources, applying systems biology and network pharmacology techniques to elucidate the molecular mechanisms of complex formula of Chinese medicine in chronic, metabolic and degenerative diseases such as thrombosis, diabetes, and aging.
Janice Aldrich-Wright, Professor, Academic lead of the WSU Science in Australia Gender Equity (SAGE) initiative, School of Science and Health, Conjoint Position School of Medicine, Western Sydney University, Australia
Prof. Dr. Ali-Osman
Francis Ali-Osman, Professor of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA
乐动体育西班牙人Mansoor M. Amiji, University Distinguished Professor and Director of the Laboratory for Biomaterials and Advanced Nano-Delivery Systems (BANDS), Department of Pharmaceutical Sciences, School of Pharmacy at Northeastern University in Boston, Massachusetts, USA
Prof. Dr. Bae
Soo Kyung Bae, Associate professor, College of Pharmacy, The Catholic University of Korea, Bucheon, Republic of Korea
乐动体育西班牙人Jonathan B. Chaires, Professor of Medicine, James Graham Brown Endowed Chair in Biophysics, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
乐动体育西班牙人James M. Cook, University Distinguished Professor, Organic Chemistry, Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA
Prof. Dr. Duan
乐动体育西班牙人Wei Duan, Alfred Deakin Professor , Deakin University School of Medicine, Melbourne, Australia.
乐动体育西班牙人Martin Egli, Professor, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA
乐动体育西班牙人Sanjay Garg, Professor of Pharmaceutical Sciences, Centre for Pharmaceutical Innovation and Development, University of South Australia, Adelaide, Australia.
Victor J Hruby, Regents Professor of Chemistry, the Department of Chemistry & Biochemistry, University of Arizona, Tucson, AZ, USA
Cyrus R Kumana, Emeritus Professor (Clinical Pharmacologist), Department of Medicine, The University of Hong Kong, Hong Kong, People's Republic of China
乐动体育西班牙人Beom-Jin Lee, Dean and Professor, College of Pharmacy, Ajou University, Korea
乐动体育西班牙人David M. Lubman, Maude T. Lane Professor of Surgery, Professor of Pathology and Chemistry, University of Michigan, Ann Arbor, MI, USA
Prof. Dr. Marcinkiewicz
Cezary Marcinkiewicz, Adjunct Professor, Department of Bioengineering, Temple University, Philadelphia, USA.
乐动体育西班牙人John J. Rossi, Lidow Family Research Chair, Professor, Department of Molecular Biology, Dean, Graduate School of Biological Sciences, Beckman Research Insitute of the City of Hope, Duarte, CA, USA
乐动体育西班牙人Wolfgang Sadee, Professor, Department of Cancer Biology and Genetics; Director, Center for Pharmacogenomics, The Ohio State University, USA; and Chief Scientific Officer, Aether Therapeutics Inc, USA.
Holger Stark, Univ.-Prof. Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-Universitaet Duesseldorf, Germany
Prof. Dr. Travagli
Valter Travagli, Professor in Pharmaceutical Technology, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
乐动体育西班牙人Mark Trudell, Distinguished Professor and Chair, Department of Chemistry, University of New Orleans, Louisiana, USA
乐动体育西班牙人Gretchen M. Unger, Chief Scientific Officer, GeneSegues, Inc., Chaska, MN, USA
Scott Waldman, Professor and Chair, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
乐动体育西班牙人Michael J. Waring, Professor of Chemotherapy, University of Cambridge, Jesus College, Cambridge, UK